Estonia, Hungary, and Iceland have signed up to take part in a pilot of Guardtime's VaccineGuard—a newly developed platform aimed at supporting the global COVID-19 vaccination program.
European deep tech company, Guardtime, has revealed that Estonia, Hungary, and Iceland have signed up to take part in a pilot of VaccineGuard—a newly developed platform aimed at supporting the global COVID-19 vaccination program.
“We are delighted that Iceland, Estonia, and Hungary have agreed to pilot our new platform,” said Ain Aaviksoo, chief medical officer, Guardtime, in a Jan. 18, 2021 press release. “These countries have been among the most proactive and most successful in developing state of the art tools and strategies for addressing Coronavirus, and we look forward to working with them on this project and sharing the findings with other countries and stakeholders to get soon back to normalcy.”
AstraZeneca Estonia will be involved in VaccineGuard product testing, enabling an end-to-end solution with a feedback loop between all participants in the network. The product pilot will be based on a six-month collaboration with the Estonian government and the World Health Organization (WHO) and is expected to be taken up by additional governments in the near future.
Through this pilot program, the Estonian government will be fulfilling an integral part of its offer to WHO and its member states to share experiences of how distributed information architecture and interoperability can be used in the fight against COVID-19.
Jüri Ratas, prime minister of Estonia added in the press release, “The pandemic has shown the world that in crisis we need to have a global anchor of trust like the WHO. [WHO] can play a critical positive role in global digital health governance. Our pilot project presents an extraordinary opportunity for the Estonian community to help the world in the fight against COVID-19.”
Source: Guardtime
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
FDA Approves Novartis Oral Treatment for Adults with C3 Glomerulopathy
March 25th 2025Fabhalta (iptacopan) received a positive opinion for treatment of C3G from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and has been approved twice before by FDA.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.